An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody

D. H. Kett, A. A. Quartin, C. L. Sprung, C. J. Fisher, M. A. Pena, S. O. Heard, J. L. Zimmerman, Timothy E Albertson, Edward A Panacek, L. A. Eidelman, R. M H Schein

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objectives: We sought to determine whether there might be acute changes in hemodynamics attributable to HA-1A, a monoclonal antibody to endotoxin, in patients with presumed Gram-negative sepsis. Design: Post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled study. Patients: A total of 543 patients with severe sepsis presumed to be caused by Gram- negative bacteria who were enrolled in a clinical trial to evaluate the efficacy and safety of HA-1A human monoclonal antibody. Interventions: Patients were randomly assigned to receive either 100 mg of HA-1A or placebo. Measurements and Main Results: Patients were grouped by the study drug, HA- 1A, or placebo, and the presence or absence of Gram-negative bacteremia. Hemodynamic variables were monitored from before, until 72 hrs after infusion of the study drug. For the entire study population (n = 543), no changes over time attributable to study drug were noted in the mean arterial pressure (p > .19), heart rate (p > .53) or the need for vasopressor administration (p > .62). One hundred ninety-seven patients underwent pulmonary artery catheterization and had hemodynamic data available from before the infusion of HA-1A or placebo until at least 12 hrs after infusion. Evaluating all 197 patients on an intent to treat basis demonstrated no significant differences over time in cardiac index (p > .15), oxygen delivery index (p > .43), or left ventricular stroke work index (p > .48) between patients who received HA-1A and those patients receiving placebo. Grouping patients by the presence of Gram-negative bacteremia and study drug received also failed to demonstrate any significant difference attributable to HA-1A in mean arterial pressure (p > .54), heart rate (p > .84), cardiac index (p > .13), oxygen delivery index (p > .05), or left ventricular stroke work index (p > .48) between populations. Conclusion: There is no apparent relationship between the administration of HA-1A, the presence of Gram-negative bacteremia, and hemodynamic profiles over the 72-hr study period.

Original languageEnglish (US)
Pages (from-to)1227-1234
Number of pages8
JournalCritical Care Medicine
Issue number8
StatePublished - 1994
Externally publishedYes


  • bacteremia
  • bacterial infection
  • blood pressure
  • cardiac output
  • endotoxins
  • Gram-negative bacteria
  • heart rate
  • hemodynamics
  • monoclonal antibody
  • shock, septic

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody'. Together they form a unique fingerprint.

Cite this